ES2186888T3 - Bencilaminas sustituidas y su utilizacion en el tratamiento de la depresion. - Google Patents

Bencilaminas sustituidas y su utilizacion en el tratamiento de la depresion.

Info

Publication number
ES2186888T3
ES2186888T3 ES97919371T ES97919371T ES2186888T3 ES 2186888 T3 ES2186888 T3 ES 2186888T3 ES 97919371 T ES97919371 T ES 97919371T ES 97919371 T ES97919371 T ES 97919371T ES 2186888 T3 ES2186888 T3 ES 2186888T3
Authority
ES
Spain
Prior art keywords
aciococococ
rent
alquiloc
heteroariloc
substitutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97919371T
Other languages
English (en)
Inventor
Dirk Casimir Maria Leysen
Gerardus Stephanus Franc Ruigt
Joannes Theodorus Mari Linders
Fredericus Antonius Dijcks
Simon James Anthony Grove
Duncan Robertson Rae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2186888T3 publication Critical patent/ES2186888T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCION SE REFIERE A CIERTOS NUEVOS DERIVADOS DEL BENCILAMINO DE LA FORMULA (I) EN LA QUE R 1 Y R 2 QUE PUEDEN SER IGUALES O DIFERENTES, SE SELECCIONAN CADA UNA ENTRE ARILOC 6-12 , HETEROARILOC 2-14 , ARILC 612 ALQUILOC 1-6 , ALQUILOC 1-6 , HETEROARILC 214 ALQUILOC S UB,1-6 (EN DONDE LA MOLECULA DE ALQUILO, ARILO O HETEROARILO PUEDE ESTAR OPCIONALMENTE SUSTITUIDA POR UNO O MAS SUSTITUYENTES SELECCIONADOS ENTRE ALCOXIDOC 1-6 , ALQUILOC 1-6 , CICLOALQUILOC 3-6 , CICLOALQUENILOC 46 , ARILOC 6-12 , HETEROARILOC 2-14 , HALOGENO, AMINO, HIDROXIDO, HALOA LQUILOC 1-6 , NITRO, ALQUILTIOC 1-6 , SULFONAMIDO, ALQUILSULFONILOC 1-6 , HIDROXIALQUILOC 1-6 , ALCOXICARBON ILOC 1-6 , CARBONILO, CARBOXIALQUILOC 1-6 , CARBOXAMIDO Y ALQUILCARBOXAMIDOC 1-6 ), HIDROGENO, ALQUILOC 1-6 , CICLOALQUILOC 3-6 , CICLOALQUENILOC 46 , ALQUENILOC SUB,2-6 , ALQUINILOC 2-6 Y ALCOXIC 16 ALQUILOC 1-6 (EN DONDE LAS MOLECULAS DE ALQUILO, CICLOALQUILO, CICLOALQUENILO, ALQUENILO, ALQUINILO O ALCOXIALQUILO PUEDEN ESTAR OPCIONALMENTE SUSTITUIDAS POR UNO O MAS SUSTITUYENTES SELECCIONADOS ENTRE AMINO, HALOGENO, HIDROXIDO, ALQUILCARBOXAMIDOC 1-6 , C ARBOXAMIDO, CARBOXIDO, ALCOXICARBONILOC 1-6 , ALQUILCARBOXIDOC 1-6 Y CARBOXIALQUILOC 1-6 ) O UNA DE R 1 Y R 2 ES COMO SE HA DEFINIDO ANTERIORMENTE Y UNA ESD HIDROXIDO; R 3 Y R 4 , QUE PUEDEN SER IGUALES O DIFERENTES, SE SELECCIONA CADA UNA ENTRE ARILOC 6-12 , HETEROARILOC SUB,2-14 , ARILOC 612 ALQUILOC 1-6 , HETEROARILOC 214 ALQUILOC 1-6 (EN DONDE LA MOLECULA DE ALQUILO, ARILO O HETEROARILO PUEDE ESTAR OPCIONALMENTE SUSTITUIDA POR UNO O MAS SUSTITUYENTES SELECCIONADOS ENTRE ALCOXIDOC 1-6 , ALQUILOC1-6 , CICLOALQUILOC 36 , CICLOALQUENILOC 4-6 , AR ILOC 6-12 , HETEROARILOC 214 , HALOGENO, AMINO, HIDROXIDO, HALOALQUILOC 1-6 , NITRO, ALQUILTIOC 1-6 , SULFON AMIDO, ALQUILSULFONILOC 1-6 , HIDROXIALQUILOC 1-6 , ALCOXICARBONILOC 1-6 , CARBONILO, CARBOXIALQUILOC 1-6 , ALQUILCARBOXAMIDOC 1-6 Y CARBOXAMIDO), HIDROGENO, ALQUILOC 1-6 , CICLOALQUILOC 3-6 , CICLOALQUILC 3-6 ALQUI LOC 1-6 , CICLOALQUENILOC 4-6 , ALQUENILOC 2-6 , ALQUINILOC 2-6 , ALCOXIC 16 ALQUILOC 1-6 , HALOALQU ILOC 1-6 , HALOALQUENILOC 26 , HALOALQUINILOC 2-6 , CIANO, CARBOXILO, ALQUILCARBOXIDOC 1-6 Y CARBOXIALQUILOC1-6 (EN DONDE LAS MOLECULAS DE ALQUILO, CICLOALQUILO, CI CLOALQUENILO, ALQUENILO, ALQUINILO O ALCOXIALQUILO PUEDEN ESTAR OPCIONALMENTE SUSTITUIDAS POR UNO O MAS SUSTITUYENTES SELECCIONADOS ENTRE AMINO, HIDROXIDO, ALQUILCARBOXAMIDOC 1-6 , CA RBOXAMIDO, CARBOXIDO, ALCOXICARBONILOC 1-6 , ALQUILCARBOXIDOC 1-6 Y CARBOXIALQUILOC 1-6 ); O UNA DE R 3 O R 4 JUNTO CON UNA DE R 1 Y R 2 Y EL ATOMO DE N AL CUAL ESTA UNIDA FORMAN UN ANILLO HETEROCICLICO DE 5 O 6 MIEMBROS, R 5 REPRESENTA UNO O MAS SUSTITUYENTES DEL ANILLO SELECCIONADOS ENTRE HALOGENO, HIDROGENO, ALQUILOC 1-6 Y ALCOXIDOC 1-6 ; Y R 6 REPRESENTA UN SUSTITUYENTE DE AN ILLO SIMPLE DE LA FORMULA (I) EN DONDE LA LINEA PUNTEADA REPRESENTA UN ENLACE OPCIONAL; Y ES OXIGENO O -NR 8 (EN DONDE R 8 ES HIDROGENO O ALQUILOC 1-6 ) Y R 7 REPRESENTA UNO O MAS SUSTITUYENTES SELECCIONADOS ENTRE HIDROGENO, HALOGENO, HALOALQUILOC 1-6 , Y ALCOXIDOC 1-6 ; TAMBIEN SE PRESENTAN LAS SALES O SOLVATOS DE LOS DERIVADOS FARMACOLOGICAMENTE ACEPTABLES. LA INVENCION SE REFIERE TAMBIEN A UN PROCESO PARA SU PREPARACION, A LAS FORMULAS FARMACEUTICAS QUE LOS CONTIENEN Y A SU USO EN TERAPIAS MEDICAS, PARTICULARMENTE EN EL TRATAMIENTO DE LA DEPRESION.
ES97919371T 1996-04-19 1997-04-15 Bencilaminas sustituidas y su utilizacion en el tratamiento de la depresion. Expired - Lifetime ES2186888T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201065 1996-04-19

Publications (1)

Publication Number Publication Date
ES2186888T3 true ES2186888T3 (es) 2003-05-16

Family

ID=8223896

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97919371T Expired - Lifetime ES2186888T3 (es) 1996-04-19 1997-04-15 Bencilaminas sustituidas y su utilizacion en el tratamiento de la depresion.

Country Status (25)

Country Link
EP (1) EP0898566B1 (es)
JP (1) JP4008033B2 (es)
CN (1) CN1139580C (es)
AR (1) AR006719A1 (es)
AT (1) ATE227278T1 (es)
AU (1) AU725847B2 (es)
BR (1) BR9708790A (es)
CA (1) CA2251820C (es)
CZ (1) CZ295747B6 (es)
DE (1) DE69716896T2 (es)
DK (1) DK0898566T3 (es)
ES (1) ES2186888T3 (es)
HK (1) HK1018271A1 (es)
HU (1) HU224637B1 (es)
ID (1) ID17723A (es)
IL (1) IL120669A (es)
NO (1) NO311976B1 (es)
NZ (1) NZ332334A (es)
PL (1) PL192561B1 (es)
PT (1) PT898566E (es)
RU (1) RU2179553C2 (es)
TR (1) TR199802104T2 (es)
TW (1) TW498070B (es)
WO (1) WO1997040027A1 (es)
ZA (1) ZA973209B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080773A (en) 1997-10-14 2000-06-27 Akzo Nobel, N.V. Benzylamine derivatives which are useful in treating psychiatric disorders
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US7125903B1 (en) 1999-09-14 2006-10-24 Aventis Pharmaceuticals Inc. Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists
ATE247110T1 (de) * 1999-09-14 2003-08-15 Aventis Pharma Inc Benzisoxazolyl-, pyridoisoxazolyl- und benzthienyl-phenoxy derivate als d4 antagonisten
US7253165B2 (en) 1999-09-14 2007-08-07 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
US7091199B1 (en) 1999-09-14 2006-08-15 Aventis Pharmaceuticals Inc. Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EP1925305A1 (en) * 2006-10-23 2008-05-28 N.V. Organon Ih channel inhibitors for the promotion of wakefulness
CA2748235A1 (en) 2008-12-24 2010-07-01 Astrazeneca Ab Ethanamine compounds and their use for treating depression
US8637551B2 (en) 2009-07-07 2014-01-28 Merck Sharp & Dohme B.V. 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives
CN102942464B (zh) * 2012-12-06 2015-04-08 西北师范大学 化合物1-(2-卤苯基)-3-甲基-丁酮-1的合成方法
CN112300061B (zh) * 2020-10-06 2022-02-18 大连理工大学 一种含氮杂环二芳酮化合物的制备方法
GB202103008D0 (en) 2021-03-03 2021-04-14 King S College London Compounds
GB202103012D0 (en) 2021-03-03 2021-04-14 King S College London Compounds
GB202103017D0 (en) 2021-03-03 2021-04-14 King S College London Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
IL120669A0 (en) 1997-08-14
DK0898566T3 (da) 2003-03-03
HUP9901434A3 (en) 2001-11-28
HK1018271A1 (en) 1999-12-17
TR199802104T2 (xx) 2000-09-21
ATE227278T1 (de) 2002-11-15
CN1219169A (zh) 1999-06-09
DE69716896T2 (de) 2003-07-24
JP4008033B2 (ja) 2007-11-14
BR9708790A (pt) 1999-08-03
NZ332334A (en) 2000-06-23
NO984836L (no) 1998-12-16
WO1997040027A1 (en) 1997-10-30
HU224637B1 (hu) 2005-12-28
HUP9901434A2 (hu) 1999-08-30
CZ334998A3 (cs) 1999-06-16
CA2251820A1 (en) 1997-10-30
IL120669A (en) 2001-04-30
AR006719A1 (es) 1999-09-08
AU2387097A (en) 1997-11-12
JP2000508672A (ja) 2000-07-11
EP0898566B1 (en) 2002-11-06
AU725847B2 (en) 2000-10-19
CA2251820C (en) 2007-03-27
PL192561B1 (pl) 2006-11-30
ID17723A (id) 1998-01-22
EP0898566A1 (en) 1999-03-03
DE69716896D1 (de) 2002-12-12
PL329348A1 (en) 1999-03-29
CZ295747B6 (cs) 2005-10-12
PT898566E (pt) 2003-03-31
NO984836D0 (no) 1998-10-16
CN1139580C (zh) 2004-02-25
RU2179553C2 (ru) 2002-02-20
ZA973209B (en) 1997-11-20
NO311976B1 (no) 2002-02-25
TW498070B (en) 2002-08-11

Similar Documents

Publication Publication Date Title
ES2186888T3 (es) Bencilaminas sustituidas y su utilizacion en el tratamiento de la depresion.
ECSP055780A (es) Derivados de indol utiles para el tratamiento de enfermedades
AR023971A1 (es) Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales
PA8570801A1 (es) Derivados del tropano utiles en terapia
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
NO20055562L (no) Substituerte indolin- og indolderivater
PA8463501A1 (es) Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp)
AR015036A1 (es) Derivados de indolilo antisicoticos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
BR0210929A (pt) Derivados de indol com afinidade para o receptor 5-ht6
DK0544821T3 (da) Indolderivater som antiallergiske og antiinflammatoriske midler
BRPI0516467A (pt) derivados indol 5-sulfonil-1-piperidinil substituìdos como antagonistas de receptor de 5-ht6 para o tratamento de distúrbios do snc
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
ECSP23095485A (es) N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
ES2084996T3 (es) Piperazinas sustituidas utiles como agentes para el sistema nervioso central.
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
BR9914255A (pt) Derivados de indolina como agentes de proteção de luz
AR048745A1 (es) Derivados de (indol-3-il)-heterociclicos
ES2184989T3 (es) Derivados de feniletanolaminotetralincarboxamida 3,4-disustituidos.
NO961797L (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
PE20011260A1 (es) Derivados de sulfonamida
CR7784A (es) Derivados de indol utiles para el tratamiento de enfermedades